IRLAB A
13.6
SEK
TODAY
-1.81 %
TODAY SEK
-0.25 SEK
16:00:00
2024-06-14
YEAR LOW
7.6 SEK
YEAR HIGH
20.2 SEK
ATH:
108.09 SEK
MCAP:
705 MSEK

CEO COMMENTS

Gunnar Olsson comments Q1 report 2024

On May 7 we announced that we signed an agreement to start a development collaboration for IRL757 with MSRD, a company within the Otsuka group. Within the framework of the agreement, together we will develop the substance to completed clinical Proof-of-Concept. The patient studies will include people with both Parkinson’s and Alzheimer’s disease. Through the collaboration agreement, IRLAB receives USD 3 million upon signing and additional activity based milestones of USD 5.5 million. In addition, MSRD/Otsuka will cover all cost for the full development program, i.a. CMC development, toxicology studies and the clinical studies.”

LATEST REPORTS

LATEST PRESS RELEASE
JUNE 11, 2024

IRLAB participates in Stora Aktiedagarna

Gothenburg, Sweden, June 11, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will give a presentation at Stora Aktiedagarna in Stockholm on June 11-12.

Read More >
LATEST PRESENTATION
MARCH 7, 2024

Fireside chat with Viktor Siewertz, CFO, at ABGSC

Viktor Siewertz, CFO, participated in the ABGSC fireside chat, moderated by Alexander Krämer, analyst at ABGSC, The event was recorded on March 5 and published on March 7, 2024.

Read More >

FINANCIAL CALENDAR

NEXT

July 10, 2024

Interim Report January – June 2024